TRP channels (including the pain-relevant TRPV1, TRPA1, TRPV3, etc.) are expressed in both the epidermis and dermis of human skin—not confined to a single layer. TRP? ----> These channels are sensory. (Think cold, warm, stinging, pain) They live within the skin layers. They are found on keratinocytes (non-neuronal skin cells) and on peripheral sensory nerve endings, plus some immune and adnexal cells. This distribution explains why topical CBD (which penetrates the stratum corneum into viable skin layers) can directly interact with them for localized pain, inflammation, and spasm relief, as discussed earlier (e.g., via TRPV1 desensitization and ECS modulation in the 2019 TMD trial) Source Paper 📃 in the comments 👇

Topical CBD (cannabidiol) has been studied for its potential to relieve localized pain and reduce inflammation when applied directly to the skin. Unlike oral CBD, topical formulations (creams, gels, oils, or balms) aim for localized effects with minimal systemic absorption, avoiding psychoactivity from THC and liver absorption (in oral CBD). Research includes preclinical (animal) models and small human clinical trials, primarily for conditions like arthritis, neuropathy, and musculoskeletal pain. Source Paper in the Links📄

Through the receptors of the Endocannabinoid System (ECS) CBD can help modulate stress and anxiety in the body.